Products
- Anti-Obesity Compound Library
- GPCR/G Protein-Targeted Compounds
- Immunology/Inflammation-Targeted Compounds
- JAK/STAT-Targeted Compounds
- MAPK-Targeted Compounds
- Membrane Transporter/Ion Channel-Targeted Compounds
- Metabolism-Targeted Compounds
- NF-κB-Targeted Compounds
- Microbiology/Virology-Targeted Compounds
- Neuronal Signaling-Targeted Compounds
- PI3K/Akt/mTOR-Targeted Compounds
- Oxidation-reduction-Targeted Compounds
- Proteases/Proteasome-Targeted Compounds
- Stem Cells/Wnt-Targeted Compounds
- Tyrosine Kinase/Adaptors-Targeted Compounds
- Ubiquitin-Targeted Compounds
Online Inquiry
(R)-Monlunabant
Cat. No.:
OB0425LY-188
Appearance:
Solid
Purity:
≥95%
Identity:
Confirmed by NMR.
Size:
Add to basket
Product Overview
Description:
(R)-Monlunabant is a selective CB1 receptor antagonist primarily used to regulate body weight and improve metabolic health.
Synonyms:
2765579-76-6; Monlunabant; (R)-MRI-1891; (R)-INV-202
CAS No.:
2765579-76-6
Compound CID:
169450732
Formula:
C26H22ClF3N6O3S
Formula Weight:
591
Specification
Target:
Cannabinoid receptor
Pathway:
GPCR/G protein; Neuronal signaling
Solubility:
DMSO
Storage:
Storage at -20°C.
Applications:
(R)-Monlunabant is primarily used in the study of obesity and diseases associated with metabolic syndrome to help reduce appetite and promote fat metabolism.
